nanotech investing Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
nanotech investing Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
nanotech investing Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
nanotech investing Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
nanotech investing Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
nanotech investing Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
nanotech investing Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
nanotech investing Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
nanotech investing Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
nanotech investing Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
nanotech investing Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Goldgroup Announces US$75 Million Private Placement with US$60 Million Already Committed by Leading Natural Resource Investors
CUAI - Copper Intelligence Extensive Drilling Program Continues to Validate Significant Copper System at Butembo, Eastern DRC
